Develops and markets pharmaceuticals for oncology, nephrology, central nervous system, and immunology. Now — the numbers.
This is an established company with proven profits.
Average growth of 9% a year over the last 4 years. Every year shown ended in profit.
If every debt were paid off today, $1.3B would still be left in the vault — a solid cushion for hard times.
The market pays 18.6× for every dollar of annual profit — around what a business like this usually costs.
No analyst target is on record for this company.
The stock trades 56% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 9% a year on average.
There is $1.4B in the vault; even if every debt were paid off, $1.3B would remain.
It pays out $0.42 per share each year — regular cash for whoever holds the stock.
Our checks did not surface a specific risk to flag here. That is not the same as there being none.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.